Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_5_presentation_1_-_birth_control_-_contraception [2020/01/31 23:59] lingh1 [References] |
group_5_presentation_1_-_birth_control_-_contraception [2020/02/13 14:51] (current) hanj35 |
||
|---|---|---|---|
| Line 87: | Line 87: | ||
| A vasectomy is a very safe procedure with minimal side effects. However, possible side effects include: swelling and bruising of the scrotum, discomfort or pain, inflammation or infection (Vasectomy Procedure: Effectiveness, Recovery, Side Effects, Pros & Cons, n.d.). | A vasectomy is a very safe procedure with minimal side effects. However, possible side effects include: swelling and bruising of the scrotum, discomfort or pain, inflammation or infection (Vasectomy Procedure: Effectiveness, Recovery, Side Effects, Pros & Cons, n.d.). | ||
| + | |||
| + | |||
| + | |||
| === Tubal Ligation === | === Tubal Ligation === | ||
| Line 107: | Line 110: | ||
| Possible side effects include: discomfort at the incision site, abdominal pain or cramping, fatigue, dizziness, shoulder pain, gassiness and bloating (Tubal ligation—Mayo Clinic, n.d.). | Possible side effects include: discomfort at the incision site, abdominal pain or cramping, fatigue, dizziness, shoulder pain, gassiness and bloating (Tubal ligation—Mayo Clinic, n.d.). | ||
| + | |||
| + | |||
| + | |||
| === Copper IUD === | === Copper IUD === | ||
| Line 178: | Line 184: | ||
| ==== Patch ==== | ==== Patch ==== | ||
| - | The first contraception patch (transdermal delivery system) developed in the 1980s was a scopolamine patch. Since then, medications that have been developed in a transdermal form include nicotine, estradiol for hormone therapy, fentanyl, clonidine, nitroglycerin, among others. For successful delivery of medication through a transdermal system, the molecule must be small and lipophilic to permeate through the skin. Estradiol and ethinylestradiol (EE) are ideal molecules as therapeutic levels can be delivered easily, whereas progesterone and progestins require higher therapeutic levels. | + | The first contraception patch (transdermal delivery system) was developed in the 1980s. It was a scopolamine patch. As medications have been improved over the years, more transdermal forms were developed. For example, the patch contains nicotine, estradiol for hormone therapy, fentanyl, clonidine, nitroglycerin, among others. For successful delivery of medication through the transdermal system, research had discovered that the molecule/hormone must be small and lipophilic to permeate through the skin. Estradiol and ethinylestradiol (EE) are ideal molecules as therapeutic levels can be delivered easily. (Galzote, Rafie, Teal, & Mody, 2017) |
| + | |||
| + | Some benefits of a transdermal patch in comparison to the oral contraceptive pill are less fluctuation in plasma concentrations of estrogen, decrease estrogen-related side effects, and nausea. Also, the users only have to change the patch once every week, as opposed to taking pill daily, which could improve the patient’s adherence. The patch perfect use ranging from 88% to 91% which is higher than the oral perfect use ranged from 68% to 85%. (Galzote, Rafie, Teal, & Mody, 2017) | ||
| - | Some benefits of transdermal patch compared to the oral contraceptive pill are less variability in plasma concentrations of estrogen, decrease estrogen-related side effects that result from high peak estrogen levels, such as nausea. Also the user only changes the patch once weekly, as opposed to taking pill daily, which could result in improved adherence. Patch perfect use ranging from 88% to 91%. Oral perfect use ranged from 68% to 85%. | ||
| == Pharmacology and pharmacodynamics == | == Pharmacology and pharmacodynamics == | ||
| - | Ortho Evra Contraceptive patch is 20cm^2 adhesive that release 35 µg EE and 150 µg norelgestromin (NGMN) per day. NGMN is an active metabolite of norgestimate, the progestin contained in the OCs Ortho-Cyclen® and Ortho Tri-Cyclen. There are three patch sizes, 10, 15, and 20 cm2, were compared in a study of 610 subjects. It was found that the 20 cm2 patch achieved ovulation suppression and cycle control similar to that of Ortho-Cyclen (6.2% 20 cm2 patch, 7.2% Ortho-Cyclen); thus, the only size patch available is the 20 cm | + | Ortho Evra Contraceptive patch is 20cm^2 adhesive patch that releases 35 µg EE and 150 µg norelgestromin (NGMN) per day. NGMN is an active metabolite of norgestimate, the progestin contained in the oral contraceptives Ortho-Cyclen® and Ortho Tri-Cyclen. Three patch sizes are available, 10, 15, and 20 cm2. (Galzote, Rafie, Teal, & Mody, 2017) |
| - | Serum levels of NGMN and EE were 20% less if worn on the abdomen compared with the buttock, thigh, or upper arm, though at all sites, the concentration remained within the reference ranges. The mean serum levels of NGMN and EE also remained within the reference range in conditions of heat, humidity, exercise, and cool-water immersion. | + | Serum levels of NGMN and EE in human body were found to be 20% less if worn on the abdomen compared with the buttock, thigh, or upper arm. However, at all sites, the concentration of NGMN and EE remained within the reference ranges. They also remained within the reference range in conditions of heat, humidity, exercise, and cool-water immersion. (Galzote, Rafie, Teal, & Mody, 2017) |
| - | The mechanism of action of NGMN and EE involves | + | The mechanism of action of NGMN and EE involves |
| + | 1. thickening the cervical mucus to block or trap sperm | ||
| + | 2. decreasing the endometrial receptivity to reduce the chance of implantation | ||
| + | 3. inhibiting ovulation by suppressing gonadotropins, FSH and LH. (Galzote, Rafie, Teal, & Mody, 2017) | ||
| - | 1. thickening the cervical mucus to prevent sperm penetration | + | Steady state concentration is reached within 2 weeks of patch use and the effect of pregnancy prevention is achieved after 1 week. The half-lives of NGMN and EE inside human body are found to be 28.4 and 15.2 hours, respectively. The mean FSH, LH, and estradiol values return to baseline levels 6 weeks after discontinuation. (Galzote, Rafie, Teal, & Mody, 2017) |
| - | + | ||
| - | 2. decreasing the endometrial receptivity to reduce likelihood of implantation | + | |
| - | + | ||
| - | 3. inhibiting ovulation by suppressing gonadotropins, follicle-stimulating hormone (FSH), and luteinizing hormone (LH). | + | |
| - | + | ||
| - | Steady state concentration is reached within 2 weeks of patch use, though pregnancy prevention is achieved after 1 week. The half-lives of NGMN and EE are 28.4 and 15.2 hours, respectively. Mean FSH, LH, and estradiol values return to baseline levels 6 weeks after discontinuation. | + | |
| == Cost of Contraception == | == Cost of Contraception == | ||
| Line 201: | Line 205: | ||
| == Efficacy == | == Efficacy == | ||
| - | In a large epidemiological trial in the UK, patients prescribed Evra™ had an incidence of 0.34 unintended pregnancies per 100 women-years. This was higher than the rate with second-generation COCs of 0.16 and 0.12 for third-generation COCs, but lower than progestin-only pills at 0.43. | + | In a large trial conducted in the UK, patients taking Evra™ had an incidence of 0.34 unintended pregnancies per 100 women-years. The founding was higher than the rate with second-generation oral contraceptives of 0.16 and 0.12 for third-generation oral contraceptives, but lower than progestin-only oral contraceptives pills at 0.43. (Galzote, Rafie, Teal, & Mody, 2017) |
| == Side Effects == | == Side Effects == | ||
| - | Given the overall higher exposure to estrogen with the patch (60% greater AUC) compared to COCs, there was concern that this could translate to an increased risk of thromboembolism events compared to women using pills | + | There is relatively higher estrogen exposure of the patch (60% greater AUC) compared to oral contraceptives. This could translate to an increased risk of VTE events compared to women using pills. (Galzote, Rafie, Teal, & Mody, 2017) |
| - | An overall incidence rate for VTE of 52.8 per 100,000 women-years in patch users and 41.8 per 100,000 women-years in NGM-35 OC users. | + | |
| + | The study showed that the overall incidence rate for VTE of 52.8 per 100,000 women-years in patch users and 41.8 per 100,000 women-years in oral contraceptive users. (Galzote, Rafie, Teal, & Mody, 2017) | ||
| == New Patches == | == New Patches == | ||
| + | (According to the study from Galzote, Rafie, Teal, & Mody, 2017) | ||
| + | |||
| EE/GSD | EE/GSD | ||
| - | * 0.5mg EE, 2.1mg gestodene | + | |
| - | * The dosing of this 11 cm2 patch results in the same amount of hormone exposure as the 0.02 mg EE and 0.06 mg GSD OC | + | * The patch contains 0.5mg EE, 2.1mg gestodene |
| - | * The EE/GSD patch has decreased EE exposure measured by the AUC compared to the EE/NGMN patch | + | * The dosing of this 11 cm2 patch have the same amount of hormone exposure as the 0.02 mg EE and 0.06 mg GSD oral contraceptive |
| - | * The incidence of breast pain was slightly lower in EE/GSD users compared to tradition EE/NGMN patch users, which is expected given the total lower estrogen exposure | + | * It can decrease the EE exposure measured by the AUC compared to the EE/NGMN patch |
| + | * The chances of having breast pain was lower in EE/GSD users compared to the traditional EE/NGMN patch users. | ||
| EE/LNG | EE/LNG | ||
| - | * 2.3mg EE, 2.6mg levonorgestrel | + | * The patch contains 2.3mg EE, 2.6mg levonorgestrel |
| - | * decreased AUC of estrogen and the use of LNG, which has been shown to have lower rates of VTE compared to other progestins. | + | * It can decrease the AUC of estrogen and the use of LNG, which can lower the rates of VTE compared to other progestins. |
| ==== Birth Control Pill/ Oral Contraceptives ==== | ==== Birth Control Pill/ Oral Contraceptives ==== | ||
| Line 394: | Line 404: | ||
| Where Can I Buy a Vasectomy & How Much Will It Cost? (n.d.). Retrieved January 31, 2020, from https://www.plannedparenthood.org/learn/birth-control/vasectomy/how-do-i-get-vasectomy | Where Can I Buy a Vasectomy & How Much Will It Cost? (n.d.). Retrieved January 31, 2020, from https://www.plannedparenthood.org/learn/birth-control/vasectomy/how-do-i-get-vasectomy | ||
| + | |||
| + | Presentation | ||
| + | {{:4m03_topic_1.pdf|}} | ||
